31 August, 2014 16:10 IST
Glenmark Q3 profit surges 4.75 times
Source: IRIS (29-JAN-13)
Comments  |  Post Comment

Glenmark Pharmaceuticals reported a surge of 4.75 times in consolidated net profit to Rs 2,129.17 million for the quarter ended Dec. 31, 2012 as compared to Rs 448.24 million in the same period last year. During the quarter, the company received out-licensing revenue of Rs. 493.03 million from Forest Laboratories.

Consolidated revenue has increased by 33.96% to Rs 13.81 billion for the quarter ended  Dec. 31, 2012 from Rs 10.31 billion in the year ago period.

Revenue from the generics business was at Rs 5.80 billion, as against Rs 4.36 billion, a growth of 33%.

Glenmark Generics Inc., U.S.A. registered revenue from sale of finished dosage formulations was Rs 4.36 billion for the quarter ended Dec 31, 2012 against revenue of Rs 3.19 billion for the previous corresponding quarter, recording an increase of 36.83%.

''We continue to maintain our high growth trajectory by recording a strong sales growth of over 30 % for the third quarter. The US, India and Russia markets performed exceptionally well and continue to drive growth for the company,'' said Glenn Saldanha, chairman and MD, Glenmark Pharmaceuticals. (Q,N,C,F)*

''The option agreement with Forest Laboratories for the development of novel mPGES-1 inhibitors and the USFDA approval for Glenmark's in-licensed molecule - Crofelemer has come as a big boost and renewed validation for our world-class Drug Discovery apabilities. While the option agreement with Forest Labs marks our seventh outlicensing deal in the innovation R&D space; the USFDA approval for Crofelemer has paved the way for Glenmark becoming the first Indian company to launch an New Chemical Entity (NCE) across multiple geographies,'' he added.

Shares of the company unchanged to settle at Rs 504.05. The total volume of shares traded was 133,269 at the BSE (Tuesday).

Surana Industries appoints Deloitte Haskins & Sells as statutory auditor - 29-Aug-2014 16:26
Zydus gets USFDA nod for Telmisartan tablets - 29-Aug-2014 13:44
Mahindra to invest an additional Rs 40 bn in Chakan - 28-Aug-2014 18:49
ONGC to invest Rs 52.2 bn in Daman project - 28-Aug-2014 17:26
CRISIL revise rating outlook to `Positive` on Shriram Transport - 28-Aug-2014 16:39
BHEL names AN Roy as a non-official director - 28-Aug-2014 15:49
Ind-Ra assigns Blue Dart's NCD issue 'AA(exp)' - 28-Aug-2014 15:49
HCL Tech in strategic pact with AppDynamics - 28-Aug-2014 15:38
Tata Motors enters Algeria with range of passenger cars - 28-Aug-2014 15:24
Ind-Ra assigns CEAT's fixed deposit programme 'A+' - 28-Aug-2014 15:15
Indraprastha Gas to buy 50 mn shares in MNGL for Rs 1.9 bn - 28-Aug-2014 15:15
* Q - Quote , N - News , C - Chart , F - Financials
Comments Post comment 
 Post Comment
Name Email
Security Code type   5q8gc8 into this box
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Forums  |   E-mail  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer